TGEN.n ($2.00) FDA removes hold on Targeted Genetics-TGEN Phase I/II clinical trials of tgAAC94 Monday, November 26 2007 - 7:34
TGEN $2.00 $0.14 (%7.53)
The FDA removed the hold on the Company's Phase I/II clinical trial of tgACC94 for inflammatory arthritis. This action follows the agency's review of the safety data to date on all 127 subjects and all data from a fatal serious adverse event, which led to a clinical trial hold in July of this year.
Market Data 
Markets 
AI
